Stock Events

Stock Events

Scrypt 

$0
3
+$0+0% Friday 00:00

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
141
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Feb 23
$0.02
Dec 20
$0.02
Oct 17
$0.21
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

30SepExpected
Q4 2015
Q1 2016
Q2 2016
Q3 2016
Q4 2016
Q1 2017
Q2 2017
-0.05
0.1
0.25
0.4
Expected EPS
N/A
Actual EPS
-0.029

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SYPT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing technologies, directly competing with Scrypt's gene therapy innovations.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine specializes in genome editing technology, similar to Scrypt's focus on gene manipulation and therapy.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a key player in CRISPR/Cas9 technology, a direct competitor in the gene editing space where Scrypt operates.
Beam Therapeutics
BEAM
Mkt Cap2.53B
Beam Therapeutics uses base editing technology, a form of gene editing that competes with Scrypt's gene therapy techniques.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicine, including gene editing, directly competing with Scrypt's technologies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals is involved in RNAi therapeutics, which can be seen as a competing approach to Scrypt's gene-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals develops RNA-targeted therapies, which are alternative approaches to Scrypt's gene therapy methods.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical offers gene therapy products, competing in the same market as Scrypt for genetic disease treatments.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals incorporates CRISPR gene editing in some of its therapy development, competing in the gene therapy field with Scrypt.

About

Scrypt, Inc. develops and provides document management and delivery solutions for regulated industries. It offers Sfax that enables users to cloud fax without printing a physical document; Stak, a healthcare document platform that transforms the workflow through a cloud-based environment; and DocbookMD, a messaging application for physicians. The company also provides XDOC, an electronic document management system that simplifies the mortgage lending process; and FaxAgent, a fax solution. It serves healthcare and lending clients, as well as service providers. The company was formerly known as SecureCare Technologies, Inc. and changed its name to Scrypt, Inc. in March 2014. Scrypt, Inc. is based in Austin, Texas.
Show more...
CEO
Dr. Richard F. Corlin M.D.
Employees
6
Country
US
ISIN
US81111J1043

Listings

OTC Link
US
SYPT

0 Comments

Share your thoughts

FAQ

What is Scrypt stock price today?▼
The current price of SYPT is $0 USD — it has increased by +0% in the past 24 hours. Watch Scrypt stock price performance more closely on the chart.
What is Scrypt stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Scrypt stocks are traded under the ticker SYPT.
What were Scrypt earnings last quarter?▼
SYPT earnings for the last quarter are -0.03 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
Does Scrypt pay dividends?▼
Yes, SYPT dividends are paid en. The last dividend per share was 0.02 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Scrypt have?▼
As of April 03, 2026, the company has 6 employees.
In which sector is Scrypt located?▼
Scrypt operates in the Information Technology sector.
When did Scrypt complete a stock split?▼
The last stock split for Scrypt was on May 21, 2007 with a ratio of 1:200.
Where is Scrypt headquartered?▼
Scrypt is headquartered in Austin, US.